🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

58 results for “CERO” Clear

  1. CER-1236

    CERO THERAPEUTICS HOLDINGS, INC.

    AML

    phase 1 small molecule active

    1 trial

  2. ExplOratory, Phase 0 Study to assess biodisTribution and PosItron EMission Tomography (PET) Imaging kinetics of [64Cu]Cu-PSMA-R2 in metaStatic prostate cancEr patients

    CERO THERAPEUTICS HOLDINGS, INC.

    metastatic prostate cancer

    phase 1 other active

    1 trial

  3. Glycerol Phenylbutyrate 1100 MG/ML [Ravicti]

    S.L

    STXBP1 Encephalopathy With Epilepsy, SLC6A1 Neurodevelopmental Disorder

    phase 1 small molecule active

    1 trial

  4. INO-3106, INO-9012

    INOVIO PHARMACEUTICALS, INC.

    Aerodigestive Precancerous Lesions and Malignancies

    phase 1 mab completed

    1 trial

  5. Prospective feasibility pilot study evaluating the value of [68Ga]Ga-PENTIXAFOR PET-CT in patients with locally advanced or metastatic Small Cell Lung Cancer (SCLC) at diagnosis and disease progression (PASSIFLORE)

    CERO THERAPEUTICS HOLDINGS, INC.

    cell lung carcinoma

    phase 1 other active

    1 trial

  6. [68Ga]Ga-PentixaFor

    CERO THERAPEUTICS HOLDINGS, INC.

    triple-negative breast cancer

    phase 1 small molecule active

    1 trial

  7. acetylsalicylic acid

    United Therapeutics Europe Ltd

    Precancerous Condition

    phase 1 small molecule completed

    1 trial

  8. CARBOPLATIN, PACLITAXEL, DOCETAXEL, VINORELBINE TARTRATE, CISPLATIN, PEMETREXED

    CERO THERAPEUTICS HOLDINGS, INC.

    Completely resected stage I or IIA non-squamous non-small cell lung cancer (NSCLC)

    approved small molecule active

    1 trial

  9. Salofalk 1000 mg granulado de liberación prolongada, Pentasa 4 g granulado de liberación prolongada, Asacol 1600 mg comprimidos gastrorresistentes, Claversal 500 mg comprimidos gastrorresistentes, Asacol 800 mg comprimidos gastrorresistentes, PENTASA 500 mg comprimidos de liberación prolongada, Pentasa 4 g granulado de liberación prolongada, Pentasa 1g granulado de liberación prolongada, PENTASA 500 mg comprimidos de liberación prolongada, Pentasa 2g granulado de liberación prolongada, Asacol 1600 mg compri

    CERO THERAPEUTICS HOLDINGS, INC.

    Ulcerative Colitis

    approved small molecule active

    1 trial

  10. The placebo MDI is formulated as a suspension of spray-dried porous particles (consisting of 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC] and calcium chloride) in a hydrofluoroalkane propellant (HFA-134a). The placebo MDI uses the same excipients as active product but with absence of the active pharmaceutical ingredient (API)., Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension

    AstraZeneca AB

    Chronic Obstructive Pulmonary Disease

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources